Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer
Although targeting IL-12 has been difficult historically, an IL-12–targeted immunotherapy has shown encouraging antitumor activity and a tolerable safety profile when administered intraperitoneally using TheraPlas technology in patients with ovarian cancer …